New Zealand Dollar: RBNZ hike seen but path questioned – Commerzbank
Volkmar Baur at Commerzbank expects the Reserve Bank of New Zealand (RBNZ) to raise rates at its July meeting to reinforce its inflation-fighting credentials, which should initially support the New Zealand Dollar (NZD). However, he argues that current market pricing of about 3.5 hikes over 12 months is excessive, and the eventual repricing of this path is likely to weigh on the kiwi.
Near term support, medium term drag
"Tomorrow morning, the Reserve Bank of New Zealand will meet to decide on its policy rate. At the last meeting in May, the decision was extremely close. The six members were divided, and since three voted in favor of raising rates and three voted against it, Governor Breman’s vote ultimately proved decisive in keeping the policy rate unchanged."
"While leading indicators suggest that inflation should now start to fall again as oil prices have dropped, it is unclear how quickly this will happen. We therefore expect the RBNZ to raise interest rates tomorrow. If only to send a clear signal that it intends to combat inflation and is firmly focused on its inflation target."
"The market has already priced in this move at a 70% probability. This should provide some support for the kiwi. However, what the central bank has to say about the coming months is likely to become a key focus for the currency once again."
"As of today, the market is pricing in about 3.5 rate hikes over the next 12 months. Given these expectations, it will likely be difficult for the RBNZ to surprise the market with a hawkish stance. However, the RBNZ is also likely to keep the door open for further rate hikes, depending on how inflation develops in the coming months. It will therefore depend on how strongly the central bank signals the possibility of another hike."
"We could certainly imagine that inflation might prove somewhat stubborn in the coming months, which could then necessitate another rate hike. However, we consider the market expectation of 3.5 hikes over the next 12 months to be excessive. Consequently, the pricing out of these hikes in the coming months is likely to weigh on the kiwi."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
As AI controversies escalate, hedge funds buy tech stocks at the fastest pace in 15 months
Hedge funds have recorded net purchases of US TMT stocks on 10 out of the past 11 trading days, rebuilding tech long positions at the fastest pace in 15 months. However, an AI policy storm has struck at the "worst possible time"—calls by AI giants to slow down development have been rejected, and regulatory uncertainty has directly hit Asian tech stocks such as Softbank. As the tech sector's bullish run coincides with Super Central Bank Week, the sector now faces a severe test.
Apple Pre-sale Tracker: iPhone 18 Pro Series Shows Weak Overseas Demand Signals, Duo Review Positive but Hardware Lags Behind
According to a survey by Jefferies, after the launch of the iPhone 18 Pro, delivery wait times in the four major markets—the US, UK, Germany, and Japan—have shortened by 5 to 11 days compared to last year, with no wait time in the US. Given stable production capacity, this is a clear sign of weak demand. Although the China and Hong Kong markets have performed better against the trend, there are still suspicions of speculative stockpiling. The new foldable Duo has been praised for its software experience, but its $2,000 price tag comes with a 254-gram body and dual-camera setup, leaving its hardware lagging significantly behind Android competitors. Jefferies maintains an "underperform" rating, with a target price implying a 21% downside from the current level.
SUI holds $0.71 support as analysts cite key buy signal, eyes on possible recovery
UBS Health Benefit Survey: Elevance Health (ELV.US) Leads, U.S. Employers Prepare for Rising Medical Costs
In the annual survey by UBS for employee benefits management institutions, Elevance Health (ELV.US) emerged as the highest-rated US health insurance company.

